TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03163550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-383
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-383
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-383
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-383
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-383
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-789
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-789
Description: Oral dose
Study: NCT00362466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Tablets, Oral, Once daily, 5-7 years
Study: NCT06157190

Intervention type: OTHER
Intervention: Unsupervised monitoring
Description: This study introduces technology-assisted rehabilitation for patients post-total hip or knee arthroplasty, utilizing wearable sensors and mobile health tech. The intervention includes:~Technology-Assisted Rehabilitation: Utilizing wearable sensors and mobile health technologies, the intervention promotes unsupervised, real-world assessments after total hip or knee replacement. It shifts from traditional supervised clinical assessments. The moveUP digital therapies platform, featuring a dedicated mobile app, acts as the primary interface for patients in rehabilitation.~Digital Biomarkers: The intervention involves gathering digital biomarkers from wearable sensors and mobile health tech. These biomarkers offer continuous, objective measurements of patients' biological and physiological data. Examples include mobility and activity level data.

Intervention type: OTHER
Intervention: Unsupervised monitoring
Description: This study introduces technology-assisted rehabilitation for patients post-total hip or knee arthroplasty, utilizing wearable sensors and mobile health tech. The intervention includes:~Technology-Assisted Rehabilitation: Utilizing wearable sensors and mobile health technologies, the intervention promotes unsupervised, real-world assessments after total hip or knee replacement. It shifts from traditional supervised clinical assessments. The moveUP digital therapies platform, featuring a dedicated mobile app, acts as the primary interface for patients in rehabilitation.~Digital Biomarkers: The intervention involves gathering digital biomarkers from wearable sensors and mobile health tech. These biomarkers offer continuous, objective measurements of patients' biological and physiological data. Examples include mobility and activity level data.
Study: NCT01186484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-212082
Description: 250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
Study: NCT03680612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime 1G - 2G / AAI101 0.5G - 0.75G
Description: Experimental drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefepime 1 g or cefepime 2 g
Description: cefepime monotherapy
Study: NCT03939663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: misoprostol 2 tablets
Study: NCT01500369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sphygmomanometer cuff inflations
Description: : Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: Placebo Comparator
Study: NCT01440517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-Maraciclatide
Description: Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
Study: NCT03535285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal ligament distraction
Description: decrease the bony resistant during canine retration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal ligament distraction
Description: decrease the bony resistant during canine retration
Study: NCT02601092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini Gastric Bypass
Description: The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass
Description: This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used.
Study: NCT04602026

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete home exercise intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Undergo physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02720640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant 'on' vs implant 'off'
Description: Single group assignment
Study: NCT03187834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Children in this arm will receive Azithromycin once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Children in this arm will receive Amoxicillin twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole
Description: Children in this arm will receive co-trimoxazole once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children in this arm will receive Placebo once a day.
Study: NCT01731834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vibrocompression and aspiration of secretions
Description: The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrocompression and aspiration of secretions
Description: The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
Study: NCT01797848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study: NCT02982018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A with new UV blocker
Description: Investigational Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: J\&J Marketed Contact Lens
Study: NCT03346551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale
Description: Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale
Description: Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the self-defining memories : Specific Questionnaire during an interview
Description: Evaluation of the self-defining memories : Specific Questionnaire during an interview

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evaluation of the self-defining memories : Specific Questionnaire during an interview
Description: Evaluation of the self-defining memories : Specific Questionnaire during an interview
Study: NCT03899064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction: Application of MC2-01 Cream, irradiation
Description: Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction: Application of MC2-01 Cream, no irradiation
Description: Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction: Applications of MC2-01 vehicle, irradiation
Description: Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction: Applications of MC2-01 vehicle, no irradiation
Description: Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Challenge: Application of MC2-01 Cream, irradiation
Description: Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Challenge: Application of MC2-01 Cream, no irradiation
Description: Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Challenge: Applications of MC2-01 vehicle, irradiation
Description: Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Challenge: Applications of MC2-01 vehicle, no irradiation
Description: Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Challenge: Control, irradiation
Description: No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Study: NCT00240110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Valproate with dose titration to achieve blood levels within the therapeutic range

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium Carbonate
Description: All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
Study: NCT05786339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tested Irbesartan Tablet
Description: T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Irbesartan Tablet
Description: R
Study: NCT02080325

Intervention type: OTHER
Group type: OTHER
Intervention: High Protein-Weight loss-Soy diet
Description: • The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).

Intervention type: OTHER
Group type: OTHER
Intervention: High Protein-Weight loss-Soy diet
Description: • The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).

Intervention type: OTHER
Group type: OTHER
Intervention: High Protein-Weight loss-Meat
Description: • The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.

Intervention type: OTHER
Group type: OTHER
Intervention: High Protein-Weight loss-Meat
Description: • The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
Study: NCT00780481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
Study: NCT01606787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mannitol
Description: After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
Study: NCT03075995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hight-fat breakfast
Description: It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
Study: NCT01247363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2608204
Description: Administered orally.
Study: NCT01231321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
Study: NCT04496375

Intervention type: OTHER
Intervention: Survey
Description: Self-completed questionnaires
Study: NCT03406416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 44Ch Bionic Eye Device
Description: Prototype wide view suprachoroidal retinal prosthesis
Study: NCT00908115

Intervention type: BIOLOGICAL
Intervention: GSK Biologicals' Infanrix™
Description: Primary and booster vaccination according to vaccination schedule. Intramuscular injection
Study: NCT00416715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium carbonate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium citrate
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium glucarate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: musculoskeletal complications management/prevention
Description: Correlative studies
Study: NCT03952715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
Study: NCT01127841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab and Bendamustine
Description: Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
Study: NCT00693641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Safe Sea sun lotion with jellyfish sting protection SPF 15
Description: Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nivea sun, caring sun lotion SPF 15
Description: The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
Study: NCT00803413

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Back School Intervention
Description: Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Supervised Walking Intervention
Description: Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Back School and Walking
Description: Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group
Description: Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
Study: NCT00906451

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Simvastatin
Description: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin
Study: NCT00499382

Intervention type: PROCEDURE
Intervention: Nuclear Medicine Cardiac Scan
Description: Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.

Intervention type: PROCEDURE
Intervention: PET/CT Cardiac Scan
Description: Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.